Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Percy Ivy

Showing results (161-170 of 232) with videos related to

Pageof 24
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Cancer|January 30, 2014
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061Michelle A Rudek, Page C Moore, Ronald T Mitsuyasu, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsGopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan, Donald L Trump, Julie L Eiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerUrsula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Pageof 24

Showing results (161-170 of 232) with videos related to

Sort By:
Pageof 24
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Cancer|January 30, 2014
A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061Michelle A Rudek, Page C Moore, Ronald T Mitsuyasu, et al.
The Oncologist|June 2, 2019
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate CancerElisabeth Heath, Lance Heilbrun, Heather Mannuel, et al.
Cancer Chemotherapy and Pharmacology|November 30, 2011
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumorsGopa Iyer, Michael J Morris, Dana Rathkopf, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.
Frontiers in Oncology|June 18, 2015
CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian CancerJung-Min Lee, Jane B Trepel, Peter Choyke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2005
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancersRamesh K Ramanathan, Donald L Trump, Julie L Eiseman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2014
Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteeChanning J Paller, Penelope A Bradbury, S Percy Ivy, et al.
Gynecologic Oncology|March 15, 2015
A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortiaIvan Diaz-Padilla, Michelle K Wilson, Blaise A Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerUrsula A Matulonis, Suzanne Berlin, Percy Ivy, et al.
Pageof 24